Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
- Author(s)
- Egeler, M; Lai-Kwon, J; Tissier, R; Fraterman, I; Kuijpers, A; Van Houdt, W; Wilgenhof, S; Rao, A; Sandhu, S; Lee, R; Eriksson, H; van Leeuwen, M; de Ligt, K; van Akkooi, A; van de Poll-Franse, L;
- Journal Title
- European Journal of Cancer
- Publication Type
- Research article
- Abstract
- BACKGROUND: While adjuvant therapy with anti-programmed cell death protein-1 (anti-PD1) for patients with resected stage III/IV melanoma has been shown to improve recurrence-free survival, the overall survival benefit remains uncertain. This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma METHODS: Data was used from two melanoma registries in Australia and the Netherlands. Patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 who completed a baseline and at least one post-baseline HRQOL assessment were included. HRQOL was assessed using the EORTC QLQ-C30 at baseline, 3, 6, and 12 months. Established thresholds were used for interpreting changes in QLQ-C30 scores. RESULTS: 92 patients were included. Mean symptom and functioning scores improved or remained stable at 12 months compared to baseline. However, a substantial proportion of patients experienced a clinically significant decline in role (39%, μ = -50.8), social (41%, μ = -32.7), or emotional (50%, μ = -25.1) functioning at 12 months compared to baseline. Younger patients were more likely to experience clinically significant deteriorations in role (OR=1.07, 95% CI: 1.02-1.13, p < 0.01) and social (OR=1.06, 95% CI: 1.01-1.11, p = 0.013) functioning. CONCLUSION: A significant proportion of patients with resected stage III/IV melanoma who received adjuvant anti-PD1 experienced clinically significant declines in role, social and emotional functioning at 12 months compared to baseline. This highlights the HRQOL issues that may arise during adjuvant anti-PD1 therapy which may require supportive care intervention.
- Publisher
- Elsevier
- Keywords
- Adjuvant anti-PD1 therapy; Health-related quality of life (HRQOL); Resected stage III/IV melanoma
- Department(s)
- Medical Oncology; Health Services Research
- Publisher's Version
- https://doi.org/10.1016/j.ejca.2024.113601
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-05 04:39:50
Last Modified: 2024-03-05 04:47:43